Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Ferrostatin-1 (Fer-1): Optimizing Ferroptosis Assays in Rese
2026-06-11
Ferrostatin-1 (Fer-1) enables precise modulation of ferroptosis in cancer biology and neurodegeneration models, acting as a nanomolar inhibitor of oxidative lipid damage. Explore advanced experimental workflows, troubleshooting insights, and the translational impact of Fer-1 in overcoming drug resistance and refining ferroptosis assays.
LY294002: Precision Control of PI3K Signaling and Synaptic M
2026-06-10
Explore LY294002, a potent PI3K/Akt/mTOR signaling pathway inhibitor, and its unique role in dissecting synaptic plasticity and cellular processes beyond conventional cancer research. This article provides advanced insights and practical assay guidance not found in existing resources.
HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus: Techni
2026-06-10
The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus enables reliable, high-yield synthesis of randomly Cy3-labeled RNA probes for applications such as in situ hybridization and Northern blotting. It is designed for research workflows requiring sensitive fluorescent RNA detection, and is not validated for diagnostic or therapeutic use.
Cytochalasin D: Mechanistic Insights and Translational Front
2026-06-09
Explore Cytochalasin D as an actin polymerization inhibitor, uncovering its unique mechanisms of action, impact on cell cycle arrest, and advanced applications in cancer and viral research. This article provides an in-depth, evidence-backed analysis with fresh insights beyond standard protocols.
Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi
2026-06-09
Anlotinib hydrochloride delivers next-generation, multi-target tyrosine kinase inhibition for precise anti-angiogenic and tumor proliferation research. This article unpacks practical workflows, troubleshooting strategies, and translational insights to maximize assay performance and data reproducibility.
Cabozantinib (XL184): Multi-Kinase Inhibition Beyond RCC Res
2026-06-08
Discover how Cabozantinib (XL184) disrupts multiple signaling pathways in cancer research, with new insights into chronic adaptation and phosphoproteomic remodeling. This article offers a deeper perspective on antiangiogenic strategy and kinase network rewiring.
Vitamin D/VDR Enhances Endometrial Decidualization via Estro
2026-06-08
This study elucidates how vitamin D, through its receptor VDR, promotes decidualization in human endometrial stromal cells by directly regulating estrogen biosynthesis and receptor expression. The findings provide mechanistic insight with potential applications for infertility research and advanced modeling of endometrial physiology.
Cardamomin Protects Against Oxidative Damage in Ischemic Str
2026-06-07
This study demonstrates that cardamomin, a chalcone from Amomum villosum, confers neuroprotection by mitigating oxidative damage and inhibiting cell death pathways in models of cerebral ischemic stroke. The findings highlight mechanistic links between cardamomin, NRF2 activation, and mitochondrial function, providing a foundation for future translational research in ischemic injury and neuroprotection.
Anlotinib Hydrochloride: Advancing Multi-Target Tyrosine Kin
2026-06-06
Anlotinib hydrochloride empowers researchers with nanomolar potency and reliable inhibition of VEGFR2, PDGFRβ, and FGFR1, outperforming other multi-target tyrosine kinase inhibitors in angiogenesis and tumor cell migration models. Its unique selectivity profile and favorable safety make it a robust tool for dissecting ERK pathway inhibition and optimizing cancer research workflows.
Cabozantinib (XL184) in RCC: Protocols, Adaptation & Trouble
2026-06-05
Cabozantinib (XL184) revolutionizes renal cell carcinoma research by enabling time-resolved dissection of kinase-driven adaptation. This guide translates recent phosphoproteomic discoveries into robust protocols, troubleshooting strategies, and advanced use-cases for signaling and motility studies.
Pazopanib Hydrochloride: Optimizing Cancer Research Assays
2026-06-05
Discover how Pazopanib Hydrochloride (GW786034) streamlines advanced in vitro cancer research, from robust protocol design to actionable troubleshooting. This guide delivers practical, data-driven strategies to maximize anti-angiogenic agent performance and reproducibility.
Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi
2026-06-04
Anlotinib hydrochloride is a potent multi-target tyrosine kinase inhibitor with nanomolar efficacy against VEGFR2, PDGFRβ, and FGFR1. It demonstrates superior anti-angiogenic and anti-proliferative activity in preclinical and clinical cancer research, with favorable safety and pharmacokinetic profiles. APExBIO supplies reference-grade anlotinib hydrochloride for research applications.
PBS (Phosphate-Buffered Saline): Technical Use and Protocols
2026-06-04
PBS (Phosphate-Buffered Saline, SKU K2818) provides a sterile, isotonic buffer that supports consistent cell washing, substance dilution, and routine in vitro laboratory workflows requiring physiological pH and osmolarity. This buffer should not be used for diagnostic or medical purposes and is strictly for scientific research applications.
PLK1-Mediated Phosphorylation of p31comet Regulates Mitotic
2026-06-03
This study clarifies how Polo-like kinase 1 (PLK1) regulates the action of p31comet in the disassembly of mitotic checkpoint complexes, revealing a phosphorylation-dependent suppression mechanism. These findings illuminate a critical control point for mitotic progression, with direct implications for the design and application of PLK1 inhibitors in cell cycle and cancer research.
Anlotinib Hydrochloride: Selective VEGFR2 Inhibition in Tumo
2026-06-03
This study characterizes anlotinib hydrochloride as a highly potent and selective multi-target tyrosine kinase inhibitor, with primary action against VEGFR2-mediated angiogenesis crucial for tumor growth. The findings highlight its superior specificity, robust anti-angiogenic activity, and favorable pharmacological profile, providing a valuable tool for cancer research and translational anti-angiogenic strategies.
8129 records 19/542 page Previous Next First page 上5页 1617181920 下5页 Last page